EVT Stock Analysis: Evotec SE | XETRA
Drug Manufacturers - Specialty & Generic | XETRA, Germany | Market Cap: 895m EUR | 12M Return: -30.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.36M
Qual. Beats: 0
Rev. Trend: -66.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Evotec SE is a Hamburg-based drug discovery and development company that partners with pharmaceutical and biotechnology firms, academic institutions, and venture capital funds to advance therapeutic candidates across a broad range of disease areas, including oncology, cardiometabolic, CNS, infectious, and rare diseases. The company operates through two segments-Shared R&D and Just – Evotec Biologics-and maintains a wide network of research collaborations with organizations such as Mass General Brigham, Joslin Diabetes Center, Novo Nordisk, BMS, Harvard, Yale, and the University of Oxford, as well as a strategic alliance with Almirall focused on immune-mediated skin diseases.
The company functions as a contract research organization (CRO) and drug discovery partner, generating revenue through fee-for-service work, milestone payments, and royalty arrangements on partnered programs. Evotec serves a diversified client base spanning large pharma, biotechs, academia, and patient advocacy groups, with operations across the US, Germany, France, the UK, and Switzerland. Originally incorporated in 1993 as Evotec AG, it adopted its current SE corporate form in April 2019 and is listed on XETRA under the ticker EVT.
- Just - Evotec Biologics revenue scales on new contract wins
- BMS and Novo Nordisk milestone payments lift Shared R&D segment
- Restructuring program targets cost savings to reach profitability
| Net Income: -193.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA 1.54 > 1.0 |
| NWC/Revenue: 38.64% < 20% (prev 46.56%; Δ -7.91% < -1%) |
| CFO/TA 0.01 > 3% & CFO 20.5m > Net Income -193.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (177.6m) vs 12m ago 0.02% < -2% |
| Gross Margin: 11.47% > 18% (prev 13.62%; Δ -2.15% > 0.5%) |
| Asset Turnover: 41.57% > 50% (prev 40.53%; Δ 1.04% > 0%) |
| Interest Coverage Ratio: -9.35 > 6 (EBIT TTM -136.7m / Interest Expense TTM 14.6m) |
| A: 0.18 (Total Current Assets 711.3m - Total Current Liabilities 423.4m) / Total Assets 1.64b |
| B: -0.55 (Retained Earnings -897.8m / Total Assets 1.64b) |
| C: -0.08 (EBIT TTM -136.7m / Avg Total Assets 1.79b) |
| D: 0.74 (Book Value of Equity 699.6m / Total Liabilities 940.2m) |
| Altman-Z'' = -0.36 = B |
| DSRI: 0.70 (Receivables 167.1m/252.8m, Revenue 745.0m/788.2m) |
| GMI: 1.19 (GM 13.62% / 11.47%) |
| AQI: 1.14 (AQ_t 0.24 / AQ_t-1 0.21) |
| SGI: 0.95 (Revenue 745.0m / 788.2m) |
| TATA: -0.13 (NI -193.9m - CFO 20.5m) / TA 1.64b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of July 14, 2026, the stock is trading at EUR 4.94 with a total of 371,645 shares traded. Over the past week, the price has changed by -4.04%, over one month by +1.19%, over three months by +5.15% and over the past year by -30.43%.
Current recommended Stop Loss: 4.70 (which is 4.9% or 1.3 ATR below the current price).
Evotec SE has no consensus analysts rating.
P/E Forward = 54.3478
P/S = 1.2014
P/B = 1.3073
P/EG = 1.4271
Revenue TTM = 745.0m EUR
EBIT TTM = -136.7m EUR
EBITDA TTM = -38.6m EUR
Long Term Debt = 298.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 88.6m EUR (from shortTermDebt, last quarter)
Debt = 409.6m EUR (from shortLongTermDebtTotal, last quarter) + Leases 22.2m
Net Debt = -35.1m EUR (calculated: Debt 409.6m - CCE 444.8m)
Enterprise Value = 860.0m EUR (895.1m + Debt 409.6m - CCE 444.8m)
Interest Coverage Ratio = -9.35 (Ebit TTM -136.7m / Interest Expense TTM 14.6m)
EV/FCF = -20.29x (Enterprise Value 860.0m / FCF TTM -42.4m)
FCF Yield = -4.93% (FCF TTM -42.4m / Enterprise Value 860.0m)
FCF Margin = -5.69% (FCF TTM -42.4m / Revenue TTM 745.0m)
Net Margin = -26.02% (Net Income TTM -193.9m / Revenue TTM 745.0m)
Gross Margin = 11.47% ((Revenue TTM 745.0m - Cost of Revenue TTM 659.6m) / Revenue TTM)
Gross Margin QoQ = -1.00% (prev 30.98%)
Tobins Q-Ratio = 0.52 (Enterprise Value 860.0m / Total Assets 1.64b)
Interest Expense / Debt = 3.57% (Interest Expense 14.6m / Debt 409.6m)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -102.6m (EBIT -136.7m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.68 (Total Current Assets 711.3m / Total Current Liabilities 423.4m)
Debt / Equity = 0.59 (Debt 409.6m / totalStockholderEquity, last quarter 699.6m)
Debt / EBITDA = 0.91 (negative EBITDA) (Net Debt -35.1m / EBITDA -38.6m)
Debt / FCF = 0.83 (negative FCF - burning cash) (Net Debt -35.1m / FCF TTM -42.4m)
Total Stockholder Equity = 789.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.82% (Net Income -193.9m / Total Assets 1.64b)
RoE = -24.55% (Net Income TTM -193.9m / Total Stockholder Equity 789.8m)
RoCE = -12.56% (EBIT -136.7m / Capital Employed (Equity 789.8m + L.T.Debt 298.8m))
RoIC = -8.09% (negative operating profit) (NOPAT -102.6m / Invested Capital 1.27b)
WACC = 9.24% (E(895.1m)/V(1.30b) * Re(12.25%) + D(409.6m)/V(1.30b) * Rd(3.57%) * (1-Tc(0.25)))
Discount Rate = 12.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.81 | Cagr: 0.16%
[DCF] Fair Price = unknown (Cash Flow -42.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.44 | # QB: 0
Revenue Correlation: -66.57 | Revenue CAGR: -1.83% | SUE: -0.34 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=-0.77 | Chg30d=-31.54% | Revisions=-40% | GrowthEPS=-36.5% | GrowthRev=-6.4%
EPS next Year (2027-12-31): EPS=-0.14 | Chg30d=+0.29% | Revisions=-25% | GrowthEPS=+81.8% | GrowthRev=+10.9%
[Analyst] Revisions Ratio: -50% (up=0, down=3)